指南与共识自身炎症与 IgG4 相关病

家族性地中海热及其并发症治疗的有效性与安全性:为EULAR/PReS家族性地中海热推荐提供依据的系统综述

Efficacy and safety of treatments in familial Mediterranean fever and its complications: a systematic review informing the EULAR/PReS recommendations for familial Mediterranean fever.
指南 / 共识 · Ann Rheum Dis · 2025-06-24

该系统性综述分析了生物制剂和托法替布治疗家族性地中海热(FMF)及合并症(如淀粉样变性)的证据,以及秋水仙碱制剂和给药策略,共纳入42项有效性与安全性研究(n=1798例患者)、13项减量研究和31项淀粉样变性研究;基于6项IL-1阻断剂随机对照试验和观察性研究,生物制剂似乎能减少发作次数、降低急性期反应物、改善疾病活动度评分和患者报告结局,且似乎相对安全;一项随机对照试验显示秋水仙碱每日一次与每日两次给药等效;AA淀粉样变性证据完全来自观察性研究,但对这一致命并发症令人安心。

要点

  • 基于6项IL-1阻断剂随机对照试验和观察性研究,生物制剂似乎能减少FMF发作次数并改善疾病活动度评分。
  • 一项随机对照试验显示秋水仙碱每日一次给药与每日两次给药等效。
  • AA淀粉样变性证据完全来自观察性研究,但对这一致命并发症的结果令人安心。

核心结论

  • 生物制剂,尤其是IL-1抑制剂,对秋水仙碱无应答的FMF患者是有效且相对安全的选择。
  • 这些治疗可能是有前景的替代方案,用于管理儿童和成人人群的症状并预防合并症。

研究设计与样本

  • 系统综述,检索MEDLINE、Embase和Cochrane Library,重点纳入2014年10月1日之后发表的研究。
  • 纳入42项有效性与安全性研究(n=1798例患者)、13项减量研究和31项淀粉样变性研究。
  • 使用Cochrane偏倚风险工具评估随机对照试验,使用纽卡斯尔-渥太华量表评估观察性研究。
  • 由于异质性过大,结果采用定性综合。

主要发现

  • 基于6项IL-1阻断剂随机对照试验和观察性研究,生物制剂似乎能减少发作次数、降低急性期反应物、改善疾病活动度评分和患者报告结局,且似乎相对安全。
  • 一项随机对照试验显示秋水仙碱每日一次给药与每日两次给药等效。
  • AA淀粉样变性证据完全来自观察性研究,但对该致命并发症的结果令人安心。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 由于异质性过大,结果采用定性综合。
  • AA淀粉样变性证据完全来自观察性研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To analyse the efficacy and safety of (1) the biological agents and tofacitinib in the treatment of familial Mediterranean fever (FMF); (2) the biological agents and tofacitinib in FMF patients with complications such as amyloidosis; and (3) the colchicine preparations and dosing strategies to serve as evidence supporting the updated European Alliance of Associations for Rheumatology (EULAR) recommendations. METHODS: This was a systematic review (SR) of studies testing pharmacological treatments in FMF patients, including targets, dosing, tapering, and uses in AA amyloidosis. MEDLINE, Embase, and the Cochrane Library were searched, focusing on studies published after October 1, 2014. The Cochrane Risk of Bias tool and the Newcastle-Ottawa Scale were used to assess the risk of bias in the included randomised controlled trials (RCTs) and observational studies, respectively. Due to excess heterogeneity, results were synthesised qualitatively. RESULTS: This SR included 42 studies for efficacy and safety (n = 1798 patients), 13 for tapering, and 31 for amyloidosis. Based on 6 RCTs of interleukin (IL)-1 blockers and observational studies, these biologicals seem to be effective in decreasing the number of attacks and acute-phase reactants and improving disease activity scores and patient-reported outcomes. They also seem relatively safe. An RCT showed the equivalence of once-daily vs twice-daily doses of colchicine. The evidence of AA amyloidosis was entirely observational but reassuring for a deadly complication. CONCLUSIONS: Biological agents, particularly IL-1 inhibitors, are effective and relatively safe options for FMF patients who do not respond to colchicine. These treatments may be promising alternatives for managing symptoms and preventing comorbidities in both paediatric and adult populations.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Sag E, Otón T, Carmona L, et al. Efficacy and safety of treatments in familial Mediterranean fever and its complications: a systematic review informing the EULAR/PReS recommendations for familial Mediterranean fever. Ann Rheum Dis. 2025. PMID: 40562663. doi:10.1016/j.ard.2025.05.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。